Emicizumab in Acquired Hemophilia A
Condition(s):Hemophilia A, AcquiredLast Updated:January 9, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Hemophilia A, AcquiredLast Updated:January 9, 2023Completed
Condition(s):Hemophilia A Without InhibitorLast Updated:April 11, 2023Terminated
Condition(s):Hemophilia A; Factor VIIILast Updated:February 16, 2024Recruiting
Condition(s):Acquired Hemophilia ALast Updated:February 26, 2024Recruiting
Condition(s):Hemophilia A With Inhibitor; Hemophilia A Without InhibitorLast Updated:July 21, 2021Recruiting
Condition(s):Haemophilia A; Haemophilia A With InhibitorsLast Updated:March 26, 2024Active, not recruiting
Condition(s):Von Willebrand Disease, Type 3; Concomitant VWD and HemophiliaLast Updated:March 1, 2023Recruiting
Condition(s):Haemophilic PseudotumourLast Updated:March 20, 2024Terminated
Condition(s):Hemophilia ALast Updated:March 6, 2024Active, not recruiting
Condition(s):Hemophilia ALast Updated:March 1, 2021Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.